SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: dalroi who wrote (928)12/4/2001 1:21:21 PM
From: tuck  Read Replies (1) | Respond to of 1784
 
stefaan,

>>concerning the WAT/ geneprot deal

did i get it correct that they pay 20m$ and get a cash infusion from wat for 10m$ ?

this smells like cisco deals<<

Yes, you got it right. It looks like WAT is getting full price for its equipment, so it makes the top line look good at the expense of risking all the profit on equity in a risky venture. Might be good for BDAL in the long run that they didn't try to beat WAT here, and I'll look to shift Trickle on weakness in BDAL and strength in WAT. For I think the market may be overreacting to the deal on both stocks.

Cheers, Tuck



To: dalroi who wrote (928)10/22/2002 3:54:58 PM
From: tuck  Read Replies (1) | Respond to of 1784
 
WAT misses and spluts. BDAL holding up well today. Is BDAL taking share or is the market getting saturated or . . . ? Will try to listen to CCs to get clues.

>>MILFORD, Mass.--(BUSINESS WIRE)--Oct. 22, 2002--Waters Corporation (NYSE:WAT - News) reported today that third quarter 2002 sales increased by 4% over prior year levels before favorable currency effects. After currency effects, reported sales growth was up 7% over the prior year. Earnings per diluted share (E.P.S.) were $0.29 for the quarter.
Douglas A. Berthiaume, Chairman and Chief Executive Officer, said, "Financial performance for the quarter was slightly below our expectations due to lower than planned mass spectrometry shipments. Our HPLC business continued to grow nicely with broad based strength across all geographical regions providing revenue growth in the low double digits. Cash flow continued to be very strong and exceeded our expectations, with $52 million of free cash flow for the quarter and $132 million year to date.

"We made significant progress on many fronts during the third quarter including the recently announced acquisition of the rheology product line of Rheometric Scientific and the initiation of a stock buyback program with $54 million of stock purchased to date. Also noteworthy, is the progress on the integration of our HPLC and mass spectrometry field operations which is advancing according to plan. We remain confident that the combined organization will enhance both the effectiveness and efficiency of our operations. We plan to record a restructuring charge in the fourth quarter."

As communicated in a prior press release, Waters Corporation will webcast its third quarter 2002 financial results conference call this morning, October 22, 2002, at 8:30 a.m. eastern time. To listen to the call, connect to www.waters.info, choose Investor Relations and click on the Live Webcast. A replay of the call will be available from today through October 28, 2002 similarly by webcast, and also by phone at 402-220-0283.

Waters Corporation holds worldwide leading positions in three complementary analytical technologies -- high performance liquid chromatography (HPLC), mass spectrometry (MS) and thermal analysis (TA). These markets account for $4.2 billion of the overall $19 billion analytical instrument market.

CAUTIONARY STATEMENT

Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company's filings with the Securities and Exchange Commission.


Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)

Three Months Ended Nine Months Ended
September 30 September 30
2002 2001 2002 2001

Net sales 216,045 202,694 633,578 610,529
Cost of sales 74,909 73,120 222,321 221,963

Gross profit 141,136 129,574 411,257 388,566

Selling, general and
administrative expenses 77,682 66,913 226,641 199,989
Research and development
expenses 13,576 11,794 38,499 34,573
Patent litigation provision - - 2,800 -
Goodwill and purchased
technology amortization 860 1,755 2,697 5,274

Operating income 49,018 49,112 140,620 148,730

Other income, net - - 116 -
Interest income, net 1,661 1,211 4,539 3,848
Income from operations
before income taxes 50,679 50,323 145,275 152,578

Provision for income taxes 11,656 12,077 33,301 36,619
Income before cumulative
effect of change in
accounting principle 39,023 38,246 111,974 115,959

Cumulative effect of change
in accounting principle (A) - - (4,506) -
Net income 39,023 38,246 107,468 115,959

Income per basic common share:
Net income before cumulative
effect of accounting
principle change 0.30 0.29 0.85 0.89
Cumulative effect of change
in accounting principle (A) - - (0.03) -
Net income 0.30 0.29 0.82 0.89

Income per diluted common share:
Net income before cumulative
effect of accounting
principle change 0.29 0.28 0.82 0.84
Cumulative effect of change
in accounting principle (A) - - (0.03) -
Net income 0.29 0.28 0.79 0.84

Weighted average number of
basic common shares 130,788 130,752 131,090 130,486

Weighted average number of
diluted common shares and
equivalents 135,483 136,704 136,511 137,560

(A) Effect at January 1, 2002 of a change in accounting method for
patent related costs.

Waters Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands)

September 30, 2002 December 31, 2001
(Unaudited)

Cash and cash equivalents 235,790 226,798
Restricted cash 69,373 -
Accounts receivable 167,594 182,164
Inventories 125,300 102,718
Other current assets 12,696 11,064
Total current assets 610,753 522,744

Property, plant and equipment, net 116,108 114,207
Other assets 262,711 249,960
Total assets 989,572 886,911

Notes payable 1,141 1,140
Accounts payable and accrued expenses 295,808 279,866
Total current liabilities 296,949 281,006

Other liabilities 25,491 24,160
Total liabilities 322,440 305,166

Total equity 667,132 581,745
Total liabilities and equity 989,572 886,911<<


Cheers, Tuck